Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Meet The Pill That Might Cure Your Jet Lag

By Motley Fool Staff - Jan 17, 2016 at 11:02AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Vanda Pharmaceuticals is in Phase III trials for a new drug that could help millions of travelers.

In this clip of Industry Focus: Healthcare, Motley Fool analyst Kristine Harjes and contributor Todd Campbell talk about how Vanda Pharmaceutical ( VNDA -1.23% ) came up with a potential cure for jet lag, what the company is working on now, and when we can expect to see results from studies. They will also examine how soon we might see the pills on shelves, and what it could mean for Vanda (and investors in the company).

A full transcript follows the video.


This podcast was recorded on Dec. 28, 2015.

Kristine Harjes: Tell me a little more about the jet lag pill.

Todd Campbell: This is an interesting one, too, because I thought, "Really? A drug for jet lag? There's really something you can do so you feel like you're on the right sleep schedule? That seems weird to me."

But sure enough, there's a company out there called Vanda Pharmaceuticals, and they have a drug that's on the market already that's being used to help people who are blind adjust their sleep cycles to the 24-hour sleep cycle. If you're blind to the point where you can't sense any light, you have a very hard time, obviously, figuring out when you should be sleeping and when you should be awake.

So, they developed a drug called HETLIOZ, and I probably pronounced that completely wrong, to help to target that. And one of the things they discovered is, "Hey, if we use this in people who have jet lag, it helps them more quickly get on the right time zone, too." So, they've done a couple smaller studies, they're going to do one confirmatory study, a phase three study, that should begin soon. And they think they could have results from that study as early as 2017.

If so, that means that people who are world travelers may have a new option, maybe as early as 2018.

Harjes: That's crazy. Label expansion for you. I have to wonder how exactly that works. How do they know just how jet lagged you are? Because you don't want to over-compensate, you know?

Campbell: I know! Obviously, they're spending all sorts of time and energy researching it. They think this could be a huge product for them, because, according to the company, Vanda Pharmaceuticals, 100 million people per year are traveling more than five time zones. So, you figure, even if a small percentage of those people can benefit from this drug, then that could make a very strong seller. So, from an investor's perspective, you might want to keep an eye on Vanda Pharmaceuticals. It's risky, but it's interesting.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vanda Pharmaceuticals Inc. Stock Quote
Vanda Pharmaceuticals Inc.
$16.02 (-1.23%) $0.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.